10 October 2024
ProBiotix Health plc
("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")
New Commercial Partnership in Mexico
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a new commercial partnership with Mexico based raw materials and ingredients specialist Raff.
Founded in 1999, Raff is a distributor of raw materials and value-added ingredients, with a particular focus on the dairy and nutraceutical sectors. Backed by a highly trained technical team, Raff specialises in the use and application of lactic and probiotic cultures, rennet, enzymes and preservatives.
Mexico has a population of 131 million people, with cardiovascular disease the single largest killer, accounting for nearly 24% of all deaths. Moreover, it is estimated that around 3.6 million people die in Mexico every year from high cholesterol. The movement from 'cure' towards 'prevention' provides a strong backdrop for the fast-growing supplement market, which should lead to a good sales opportunity for ProBiotix.
The five-year agreement enables Raff to act in partnership with ProBiotix, as the exclusive distributor of LPLDL® to be used as an ingredient for the local manufacturing of finished products. The launch is planned for the first half of 2025, with commercial sales expected in late 2025/early 2026.
Steen Andersen, CEO of ProBiotix, commented: "After lengthy discussions we are delighted to announce our partnership with Raff and firmly believe that they share our ethos - to develop innovative products to help enrich individuals with healthier lives.
"The cardiovascular drug market in Mexico is estimated to be worth $2.2 billion this year, and provides a huge latent opportunity. With an ageing population, we believe Mexico provides a highly attractive market for ProBiotix to target."
Rafael Gonzalez, Commercial Director of Raff, added: "As an already well established probiotics supplier in the Mexican market through our relationship with Italy based Sacco Systems, having the opportunity to partner with ProBiotix Health, being a pioneer within probiotics and cardiometabolic health, is extremely exciting for us.
"We welcome the opportunity to expand our portfolio with a unique well documented precision biotic like LPLDL®. It is our belief that LPLDL® fills an untapped potential in the fast growing Mexican supplement market, and that the product sits well with our already strong position in the sector."
For further information, please contact:
| ProBiotix Health plc | https://probiotixhealth-ir.com/ |
| Steen Andersen, Chief Executive Officer | Contact via Walbrook below |
| | |
| Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) |
|
| Mark Anwyl
| Tel: 020 7220 9793 |
|
| |
| Walbrook PR Ltd | probiotix@walbrookpr.com |
| Anna Dunphy | Mob: 07876 741 001 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
